We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

121 hedge funds and large institutions have $810M invested in ArriVent BioPharma in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 40 increasing their positions, 35 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

61,858% more call options, than puts

Call options by funds: $7.43M | Put options by funds: $12K

100% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 15

14% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 35

14% more funds holding

Funds holding: 106 → 121 (+15)

14% more capital invested

Capital invested by funds: $712M → $810M (+$97.8M)

2.07% more ownership

Funds ownership: 95.07% → 97.14% (+2.1%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
121
Holders Change
+15
Holders Change %
+14.15%
% of All Funds
1.47%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
30
Increased
40
Reduced
35
Closed
15
Calls
$7.43M
Puts
$12K
Net Calls
+$7.42M
Net Calls Change
+$8.75M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$9.54M
2
SCM
Suvretta Capital Management
New York
+$8.38M
3
BlackRock
BlackRock
New York
+$6.8M
4
Goldman Sachs
Goldman Sachs
New York
+$6.46M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.16M

Top Sellers

Rank Fund Capital Flow
1
SL
Siren LLC
Connecticut
-$12.9M
2
HA
HHLR Advisors
Cayman Islands
-$11.6M
3
CLG
Cooperman Leon G
-$7.77M
4
Morgan Stanley
Morgan Stanley
New York
-$6.13M
5
Franklin Resources
Franklin Resources
California
-$4.73M
Name Holding Trade Value Shares
Change 		Change in
Stake
IAM
1
Infinitum Asset Management
Florida
$83M +$5.31M +255,000 +7%
SCM
2
Suvretta Capital Management
New York
$82.6M +$8.38M +402,583 +11%
HA
3
HHLR Advisors
Cayman Islands
$79.1M -$11.6M -555,555 -12%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$74.5M +$6.16M +296,023 +9%
O
5
OrbiMed
New York
$60.9M – – –
BlackRock
6
BlackRock
New York
$47.7M +$6.8M +326,700 +16%
OCA
7
Octagon Capital Advisors
New York
$39.7M – – –
NHAS
8
Novo Holdings A/S
Denmark
$39.1M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$37.6M -$3.34M -160,265 -8%
SI
10
Sofinnova Investments
California
$34.1M – – –
GCGM
11
General Catalyst Group Management
Massachusetts
$30.1M – – –
State Street
12
State Street
Massachusetts
$22M +$1.34M +64,352 +6%
HH
13
HSG Holding
Hong Kong
$16.7M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$15.2M +$775K +37,231 +5%
Goldman Sachs
15
Goldman Sachs
New York
$14.9M +$6.46M +310,587 +72%
ACM
16
AIHC Capital Management
$13M +$13.4M +644,788 New
F1I
17
Fund 1 Investments
Puerto Rico
$11.4M -$1.12M -54,000 -9%
Citadel Advisors
18
Citadel Advisors
Florida
$9.23M +$9.54M +458,502 New
UBS Group
19
UBS Group
Switzerland
$9.07M -$972K -46,681 -9%
Millennium Management
20
Millennium Management
New York
$5.67M -$86.4K -4,152 -1%
Charles Schwab
21
Charles Schwab
California
$5.04M +$148K +7,102 +3%
Northern Trust
22
Northern Trust
Illinois
$4.94M +$300K +14,432 +6%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$4.89M +$5.05M +242,828 New
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$4.69M +$4.86M +233,324 New
Point72 Asset Management
25
Point72 Asset Management
Connecticut
$4.36M +$4.51M +216,660 New
1
2 3 4 5

AVBP Hedge Fund Activity: Q4 2025 in Review

121 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q4 2025, worth a combined $810M — up 14% from $712M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new AVBP positions and 15 closed out — a net gain of 15 holders — while 40 added to existing stakes and 35 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $9.54M. The largest seller was Siren LLC, exiting entirely with an estimated $12.9M sold.

  • 121 institutional investors held ArriVent BioPharma (AVBP) as of Q4 2025, up from 106 in Q3 2025.
  • Funds reported $810M of ArriVent BioPharma stock for Q4 2025, up 14% quarter-over-quarter.
  • 30 funds opened new ArriVent BioPharma positions in Q4 2025 and 15 closed out, a net change of +15 holders.
  • The largest ArriVent BioPharma buyer in Q4 2025 was Citadel Advisors, an estimated $9.54M added.
  • The largest ArriVent BioPharma seller in Q4 2025 was Siren LLC, an estimated $12.9M sold.

Based on aggregated 13F filings for Q4 2025.